The impact of HER2 discordance on patient prognosis following anti-HER2 neoadjuvant therapy for HER2-positive breast cancer
Frontiers in Oncology · 04.08.2026 · 16
DOI: 10.3389/fonc.2026.1889796 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 04.08.2026. Verfasst von Yining Ren und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Hebei Provincial Hospital of Chinese Medicine/The First Affiliated Hospital of Hebei University of Chinese Medicine, S…. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Human epidermal growth factor receptor 2 (HER2) discordance between biopsy and residual disease (RD) is common in HER2-positive breast cancer (BC) after anti-HER2 neoadjuvant therapy (NAT). This study investigated the impact of HER2 discordance on oncological outcomes.
Methods
Consecutive HER2-positive BC patients who received anti-HER2 NAT were identified from a prospective database. HER2 status was evaluated for both biopsy specimens and RD before and after NAT. The prognostic implications of HER2 discordance were assessed.
Results
A total of 700 HER2-positive BC patients were enrolled, 267 (38.1%) of whom achieved pathological complete response (pCR) after NAT. For patients with RD after NAT, the HER2 status of RD was HER2 (3+) in 209 (29.9%), HER2 (2+) in 144 (20.6%), and HER2 (1+ or 0) in 80 (11.4%) patients. A total of 217 patients exhibited HER2 changes after NAT, including 183 (26.1%) cases with loss and 34 (4.9%) with gain of HER2 positivity. There was no significant difference ( P >0.05) in 5-year invasive disease-free survival (IDFS) between patients with different HER2 statuses of RD after NAT (87.3%, 84.2% and 80.9% for no change, loss and gain of HER2 positivity, respectively). Multivariate analysis indicated that cN+ (HR 3.946, 95% CI 1.535-10.148; P = 0.004), Miller-Payne grade of 3-4 (HR 0.499, 95% CI 0.278-0.933; P = 0.040) and pre-NAT HER2 (3+) (HR 0.479, 95% CI 0.251-0.915; P = 0.026) were independent prognostic factors for IDFS in patients without pCR after anti-HER2 NAT.
Conclusion
HER2 discordance after anti-HER2 NAT was observed in a substantial proportion of HER2-positive BC patients. However, neither the change of HER2 nor the specific HER2 status after NAT was associated with the prognosis. Moreover, pre-NAT HER2 status was a robust prognostic factor in HER2-positive BC patients who received anti-HER2 NAT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery, Hebei Provincial Hospital of Chinese Medicine/The First Affiliated Hospital of Hebei University of Chinese Medicine, Shijiazhuang, China.
- Department of General Surgery, Xilin Gol League Central Hospital, Xilinhot, China.
- Department of Health Care, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Thyroid and Breast Surgery, Peking University First Hospital, Beijing, China.
Zitieren
APA
Ren, Y., Su, T., Gong, Z., Li, G., Feng, H., Feng, X., Zhou, S., & Xing, W. (2026). The impact of HER2 discordance on patient prognosis following anti-HER2 neoadjuvant therapy for HER2-positive breast cancer. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1889796
Vancouver
Ren Y, Su T, Gong Z, Li G, Feng H, Feng X, et al. The impact of HER2 discordance on patient prognosis following anti-HER2 neoadjuvant therapy for HER2-positive breast cancer. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1889796
BibTeX
@article{Ren2026,
author = {Ren, Yining and Su, Tianlong and Gong, Zixing and Li, Guolei and Feng, Hao and Feng, Xinyu and Zhou, Sicheng and Xing, Wei},
title = {The impact of HER2 discordance on patient prognosis following anti-HER2 neoadjuvant therapy for HER2-positive breast cancer},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1889796}
}
EUVIMED